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Introduction 
 
 
 
Epidemiology and classifications of neuroendocrine neoplasms  
Neuroendocrine neoplasms (NEN) are a heterogeneous group of malignancies, arising from the 
diffuse neuroendocrine system, with variable histology and clinical behavior. In the last decades the 
incidence of NEN has considerably increased from 1.09 per 100,000 in 1973 to 6.98 per 100,000 and 
this increase occurred across all sites, stages, and grades (1). Since the diffuse neuroendocrine 
system is located in almost every tissue, NEN can virtually occur in any organ of the human body, 
but the predominant site of localization is the gastrointestinal tract (67%), followed by the 
bronchopulmonary tract (25%). NEN are mostly sporadic (~80%) but may be associated to genetic 
syndromes as multiple endocrine neoplasia type 1 (MEN1), von Hippel Lindau syndrome (VHL), 
neurofibromatosis type 1 and tuberous sclerosis. Age of onset is considerably variable, but NEN 
more frequently occur in the sixth decade, except when related to inherited syndromes, when their 
onset is significantly anticipated (2). Although NEN have mainly an indolent course, about 50% of 
newly diagnosed patients already present with metastases, requiring an effective systemic 
treatment to prolong survival. Liver, lymph nodes and bone represent the most common sites of 
metastases. The identification of metastases has a negative impact on prognosis, as in patients with 
localized disease, 5-year survival rates range from 78% to 93%, while in metastatic NEN, 5-year 
survival is poor, between 19% and 38%, although survival has increased over the last two decades 
(3, 4). 
As stated by the last World Health Organization (WHO) classification, gastroenteropancreatic (GEP) 
NEN are divided into three categories with increasing malignant potential, according to proliferative 
activity as defined by Ki67 index: well differentiated G1 neuroendocrine tumors (NET) (Ki67 ≤2%), 
moderately differentiated G2 NET (Ki67 3-20%), and poorly differentiated G3 or neuroendocrine 
carcinoma (NEC) (Ki67>20%) (5) (Table 1). The grading system mainly determines the therapeutic 
strategy and prognosis of NEN, since histologic differentiation and proliferative activity are the 
strongest predictors of survival. According to the 2015 WHO classification, thoracic neuroendocrine 
tumors are classified into typical carcinoid, atypical carcinoid, large-cell neuroendocrine carcinoma, 
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and small-cell neuroendocrine carcinoma, based on the mitotic activity and the presence/absence 
of necrosis (6) (Table 2). The knowledge of genetic alterations is now expanding, thus allowing new 
insight into the molecular basis of NEN and hopefully new classifications will take these aspects into 
account.  
 
Clinical presentation  
Clinical presentation of NEN is widely variable mainly according to site of origin, stage of disease 
and hormone secretion. NET are usually slow-growing and frequently (~70%) non-functioning, with 
nonspecific clinical presentation as local symptoms caused by mass effect or obstruction and 
bleeding. Diagnosis of non-functioning NET can be often delayed or even incidental, when 
metastases have already developed. 
About 25-30% of NET are functional, mainly arising in the digestive system, and manifest with 
specific syndromes related to hormone secretion. The diagnosis of functional NET requires the 
demonstration of an inappropriate elevation of specific serum markers together with distinct clinical 
symptoms (7). Functional NET are typically well differentiated G1 and G2 tumors arising in the 
endocrine pancreas or the small intestine. The most common NET-related clinical syndromes are 
carcinoid syndrome, hyperinsulinemic hypoglycemia, and the Zollinger-Ellison syndrome. Carcinoid 
syndrome occurs in approximately 30-40% of patients affected by midgut NET, though its real 
incidence is difficult to assess and widely varies in different studies. Carcinoid syndrome mainly 
presents with recurrent skin flushing, diarrhea, and fibrotic valvular right heart disease, mediated 
by serotonin secretion, thus 24-h urinary excretion of the downstream serotonin metabolite 5-
hydroxyindoleacetic acid (5-HIAA) is elevated in affected patients (8). Hypoglycemic 
hyperinsulinemic syndrome is characterized by inappropriate increased levels of insulin in the 
presence of low plasma glucose concentrations and commonly occurs in pancreatic insulinomas. 
The Zollinger-Ellison syndrome is characterized by recurrent peptic ulcers, diarrhea and 
malabsorption due to hypergastrinemia induced by a gastrin-secreting duodenal-pancreatic NET. 
Clinical syndromes due to vasoactive intestinal peptide (VIP), glucagon or somatostatin-secretion 
are rare. Other rare entities include the paraneoplastic secretion of ACTH/CRH (adrenocorticotropic 
hormone/corticotropin-releasing hormone), GHRH (human growth hormone-releasing hormone), 
PTHrp (parathyroid hormone-related protein), calcitonin (9) (Table 3). Symptoms of functional NET 
may allow early detection, but on the other hand the effects of hypersecretion can increase 
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mortality (10). Since the clinical presentation, natural history and prognosis widely differ among NET, 
there is a critical need to identify accurate diagnostic, prognostic and predictive biomarkers. About 
40 circulating analytes of varying sensitivities and specificities have been developed in the last 
decades, but hormonal workup should always be guided by the presence of symptoms arising from 
excess hormone production (11, 12). Chromogranin A (CgA) is the most widespread NET biomarker, 
a constitutive product of the neuroendocrine secretory granule, which can be measured in serum 
or plasma. The sensitivity of CgA is about 60-90%, but its specificity is less than 50%, due to possible 
raise in many other common conditions as renal failure, cardiac disease, non-neuroendocrine 
tumors, and therapy with proton-pump inhibitors. The urinary metabolite of serotonin, 5-HIAA is a 
reliable marker of carcinoid syndrome of predominantly midgut origin. Other biomarkers of specific 
tumor syndromes are insulin for insulinoma and gastrin for gastrinoma respectively (Table 4). 
NEN management hopefully requires a multidisciplinary approach involving assessment by a 
surgeon for resection, and systemic or locoregional treatment in cases of unresectable or recurrent 
disease. Treatment decision in NEN should consider tumor differentiation, grade and stage as well 
as concomitant symptoms, mainly mass effect and hormone production, along with patients’ 
characteristics, as age, performance status and life expectancy. In the choice of the therapy, care 
must be taken to the quality of life of patients, balancing potential risks and benefits. Due to the 
long natural history, patients are often treated with more therapeutic lines. Besides surgery, first-
line therapy is usually represented by somatostatin analogs (SSA), and after progression targeted 
therapies (everolimus and sunitinib), chemotherapy, peptide receptor radionuclide therapy (PRRT) 
are used in different sequences of treatment (13). 
 
Therapy with somatostatin analogs  
Native somatostatin consists of two cyclic peptides of 14 and 28 amino acids with inhibitory role in 
several functions, including gastrointestinal motility and the secretion of pancreatic and intestinal 
hormones. The extremely short half-life of native somatostatin (<3 min) and the post-infusion 
rebound hypersecretion of hormones limit its clinical usefulness (14). The demonstration of 
somatostatin receptors on the surface of most NET’s cells has led to the development of synthetic 
SSA, whose introduction in clinical practice represented a turning point in NET therapy (15). The two 
commercially available SSA, namely octreotide and lanreotide, are usually the first-line therapy in 
patients with well or moderately differentiated NET, due to their inhibitory activity in controlling 
hormone excess and related syndromes. Both octreotide and lanreotide show high affinity for 
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somatostatin receptor subtypes (SSTR) 2 and 5, and are now available for either short or long acting 
release (LAR) formulations. The availability of LAR formulations administered once monthly instead 
of requiring daily subcutaneous (s.c.) injections, represented a major clinical breakthrough. The 
introduction of SSA in clinical practice resulted in a substantial improvement of patients' quality of 
life and survival. Indeed, the comparison of survival rates in patients who received diagnoses of NET 
from 1973 to 1987, with those who received diagnoses from 1988 to 2004 showed improvement 
among patients with metastatic disease (HR 0.67; 95% CI, 0.62 to 0.73; P.001). Since octreotide was 
the only new drug introduced for NET treatment during this period (in 1987), it was the introduction 
of SSA to have a positive impact on the survival of NET patients (3).  
Octreotide and lanreotide are effective in controlling most NET endocrine syndromes. In functioning 
NET, it is reported a complete or partial clinical response in 70-90% of patients and usually at least 
50% of patients with clinical symptoms respond to SSA (14, 16, 17). Furthermore in vitro studies 
have documented an antiproliferative effect of SSA through both direct and indirect mechanisms 
(18-20). Initially the antiproliferative effect has been highlighted for short acting SSA in some small 
series and case reports (21-24) showing significant reduction or complete regression of tumor and 
metastases. Nevertheless, in most studies, stabilization is reported as best tumor response in about 
50% of patients treated with SSA in mono or combined therapy (16, 25, 26).  
The role of SSA in the therapeutic management of NET has expanded in the last years. Two phase III 
clinical trials, namely PROMID and CLARINET, have clearly documented an antiproliferative effect 
for octreotide and lanreotide respectively (27, 28). In particular, the PROMID study demonstrated 
that administration of octreotide LAR 30 mg monthly allowed to obtain a 2-fold prolongation of the 
time to tumor progression in patients with well-differentiated metastatic neuroendocrine midgut 
tumors compared with placebo (27). Subsequently, the CLARINET study evaluated the anti-
proliferative activity of lanreotide Autogel 120 mg monthly vs. placebo in patients with advanced, 
well or moderately differentiated (Ki67< 10%) NET arising from midgut, pancreas, and hindgut as 
well as of unknown primary site with or without disease progression. The CLARINET study showed 
that lanreotide Autogel was associated with prolonged progression-free survival (PFS) compared to 
placebo (median not reached vs. median 18 months, P<0.001) (29). More recently, long-term results 
of both studies have become available. The follow-up study of PROMID provides data of long-term 
survival. The median overall survival was only slightly different in patients treated with octreotide 
or placebo (84.7 and 83.7 months) [HR = 0.83 (95% CI:0.47–1.46); p = 0.51], though crossover of the 
majority of placebo patients to octreotide LAR may have hampered the data (30). The CLARINET 
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open-label extension (OLE) study reported long-term safety and additional efficacy data in patients 
with metastatic G1 G2 non-functioning pancreatic, midgut or unknown primary NET. Patients with 
stable disease (SD) at core study end, who were treated either with lanreotide or placebo or PD 
(placebo only), continued or switched to lanreotide in the OLE. Patients continuing lanreotide 
reported fewer adverse events during OLE than core study, and patients switched to lanreotide 
reported similar adverse events rates in OLE and core studies, except more diarrhea. Median 
lanreotide PFS was 32.8 months (95% CI: 30.9, 68.0). Thus, this OLE study suggests that long-term 
treatment with lanreotide Autogel 120 mg maintained favourable safety and tolerability, and data 
also provide new evidence of lanreotide anti-tumor efficacy (30).  
Currently, as reported in the most reliable and widespread international guidelines (ENETS, NCCN), 
long-acting SSA octreotide and lanreotide are considered as a keystone of therapy, both due to their 
direct inhibitory effect on tumor hormone production and antiproliferative activity, with minimal 
adverse effects (31, 32). The most common adverse events include abdominal pain with cramps, 
constipation, diarrhea, steatorrhea, injection site irritation and local pain, nausea and vomiting. Less 
frequent adverse events are hypothyroidism and cholecystitis. Acute pancreatitis, alopecia, acute 
hepatitis, hyperbilirubinemia, hyperglycemia, hypoglycemia, prolonged QT interval and arrhythmias 
are rare but still possible complications (33). A relevant adverse effect is the development of 
gallstones, in up to 60% of patients, deriving from inhibition of cholecystokinin release which in 
postprandial induces emptying of the gallbladder (34).  
The treatment with long-acting preparations of standard dose SSA consists in an intramuscular 
injection of octreotide-LAR 30 mg or lanreotide Autogel 120 mg every 4 weeks. Nevertheless, there 
has been a general trend supporting the use of high doses of octreotide LAR or lanreotide Autogel 
to control symptoms and tumor progression in patients with NEN, after progression under standard 
SSA dose (35). A study using biopsy specimens taken before and during SSA using low and high doses, 
showed that apoptosis in NET was induced only by high dose SSA (36). Furthermore, a substantial 
number of NET patients escape from treatment within months and the potential mechanisms 
involved in desensitization to SSA, yet largely unknown, include down-regulation of SSTR as well as 
the outgrowth of clones lacking the expression of SSTR, which the currently available SSA bind with 
high affinity (37). Nonetheless, there is evidence suggesting that in some patients escape could be 
overcome by increasing the dosage of SSA. Some studies suggested that the antiproliferative effect 
of SSA could be dose-dependent in progressive or metastatic NET (36, 38-41). The effect of 
shortened interval of octreotide LAR was prospectively investigated in a series of 28 well or 
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moderately differentiated NET with promising results (42). Octreotide LAR 30 mg administered 
every 21 days in well differentiated NET with progressive disease at standard-dose interval, resulted 
in complete and partial control of clinical symptoms in 40% and 60% of cases, respectively. 
Circulating neuroendocrine markers were significantly decreased in 30% of cases. A stabilization of 
disease was obtained in 93% and objective response in 7%. The median time to progression (TTP) 
was significantly longer by using the shortened interval of LAR administration as compared to the 
standard one (30 vs 9 months, p<0.0001). Furthermore, data derived from retrospective studies as 
well as from few prospective trials, generally support the switch to high dose SSA in patients with 
disease progression and/or uncontrolled symptoms (43-45), thus increasing SSA dose or shortening 
the dosing interval have become common clinical practice. 
However, to date, systematic prospective trials evaluating safety and efficacy of high dose SSA in 
NET are still lacking, and experience is largely borrowed from high dose schedules in acromegaly (46, 
47). 
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Aim of the study 
 
 
 
The primary objective of this study was to evaluate the efficacy of two different high-dose SSA 
schedules (octreotide LAR 60 mg administered every 28 days and lanreotide Autogel 120 mg 
administered every 21 days) in NET patients with progressive disease under standard SSA dose for 
at least 6 months.  
Secondary aims were the evaluation of the objective response rate (ORR), the clinical response and 
the biochemical response, together with safety assessment. 
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Patients and methods 
 
 
 
This is a phase 2, single center, prospective, open label study. The study population consisted of 20 
consecutive patients, 14 males (70%) and 6 females (30%), mean age 54.2 ± 14.7 years (range 22-84 
years) enrolled among patients with NET in follow-up at the Unit of Neuroendocrine Tumors, 
Department of Clinical Medicine and Surgery, ‘Federico II’ University Hospital of Naples. The patient 
population included patients with histologically confirmed diagnosis of well or moderately 
differentiated NET (G1 or G2), as defined by the last WHO classification criteria for GEP NET, 
bronchial, and thymic origin (4, 5). Tumor stage was evaluated according to the last TNM 
classification (48). All included patients had tumor progression (either radiological or clinical) under 
a standard-dose treatment with SSA (Octreotide LAR 30 mg every 28 days or Lanreotide Autogel 120 
mg every 28 days) for at least 6 months (mean 34.7 ± 38.8 months, range 6-119). Progressive disease 
was defined as increased tumor size according to the “Response evaluation criteria in solid tumors” 
(RECIST) definitions (49). Patients were enrolled in accordance with international standards of good 
clinical practice and written informed consent document was provided by patients or their legal 
representatives. To be eligible for the study, patients were required to be adult aged at least 18 
years with histologically proven NET, and at least one lesion that could be accurately measured by 
spiral computed tomography scan. Subjects were excluded from participation if they had known 
hypersensitivity to SSA, prior or concomitant malignancies other than NET, unstable systemic 
diseases, pregnancy or breast-feeding, any active or uncontrolled infection/disorder, psychiatric 
condition or laboratory abnormality that may increase the risk associated with study participation 
or study drug administration, or may interfere with the interpretation of study results, and in the 
judgement of the investigator would make the patient inappropriate for entry into this study.  
Baseline characteristics of the patients are shown in Table 5. Twelve patients had sporadic NET (60%) 
and 8 patients had MEN1-related NET (40%). Primary tumor sites were mainly in the gastro-entero-
pancreatic tract (10 pancreas, 5 ileum, 1 duodenum, 1 rectum), 2 bronchial. In one case, the primary 
tumor site was unknown. Ki67 index was available in all patients: 12 patients (60%) had Ki67 ≤ 2% 
(G1) and 8 patients (40%) had Ki67 3-20% (G2). 
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Metastases were diagnosed in 15 (75%) patients, mainly to the liver 13 (65%), and 2 (10%) patients 
had locoregional lymph node metastases. In 5 (25%) patients there was no evidence of local or 
distant metastases. Surgical resection of the primary tumor was performed in 8 (40%) patients 
before starting SSA. No other previous antitumor treatment was performed. All the included 
patients underwent functional assessment of SSTR positivity with either Octreoscan or 68GaPET 
before starting therapy with SSA. NET was non-functioning in 10 (50%) and functioning in 10 cases 
(50%). Among functioning NET there were 5 carcinoid syndromes, 4 Zollinger Ellison syndromes and 
1 paraneoplastic acromegaly. At study entry, neuroendocrine markers and clinical symptoms were 
not controlled in 20 (71%) and 19 (68%) patients, respectively. At study entry, 9 of the 10 patients 
with functioning NET were receiving therapy with either loperamide or proton pump inhibitors, 
according to the specific symptoms. CgA was evaluated as aspecific neuroendocrine biochemical 
marker in every patient, while 24-h urinary 5-HIAA, serum gastrin and IGF-1 levels were determined 
in functioning NET as specific markers for carcinoid syndrome, Zollinger Ellison syndrome and 
paraneoplastic acromegaly, respectively. All patients presented with good performance status 
(ECOG grade 0 or 1). 
The following therapeutic options with high dose SSA were evaluated: octreotide LAR 60 mg every 
28 days and lanreotide Autogel 120 mg every 28 days. During high dose SSA therapy, patients 
maintained symptomatic treatments (loperamide, proton pump inhibitors) according to their 
symptoms.  Patient enrollment started in November 2015, the mean follow-up was 29.9 ± 4.6 
months (range 20-35). High dose SSA was started after disease progression with SSA at standard 
dose: radiological in 17 patients, clinical in 2, both radiological and clinical in 1 patient. Study 
duration was 36 months, including screening, treatment and follow-up. 
 
Efficacy 
Efficacy was evaluated by median PFS (mPFS), objective response rate (ORR), clinical and 
biochemical response. Radiological, clinical and biochemical data were recorded for every patient 
before starting high dose SSA treatment and every 3-6 months during follow-up. PFS was defined as 
the time from first study drug administration (high dose SSA) to objective tumor progression. If a 
patient had not had an event, PFS was censored at the date of last adequate tumor assessment. 
ORR evaluation included complete response (CR), partial response (PR), stable disease (SD) and 
progressive disease (PD) evaluated by contrast enhanced computed tomography (CT) or magnetic 
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resonance imaging (MRI), according to the RECIST1.1 criteria, using the same technique at baseline 
and during follow-up. 
Biochemical response was evaluated by neuroendocrine marker (one or more), if abnormally 
increased before starting high dose SSA treatment. CR was defined as normalization of 
neuroendocrine marker, PR as reduction ≥ 50% in at least one marker, no response as variation 
<50%, progression as increase ≥ 50%. 
Clinical evaluation was based on symptom referred at baseline and during follow-up, using an 
analogical scale (score range 0-3: 0 no symptoms, 1 mild, 2 moderate, 3 severe). Both symptoms 
related to endocrine syndrome, such as flushing, diarrhea, and aspecific symptom, such as 
abdominal pain were evaluated. Complete response was defined as total regression of symptoms 
from whatever score to score 0, partial response was defined by symptom decrease of at least 1 
point not reaching score 0. 
The variations of symptomatic drugs dose (loperamide, proton pump inhibitor) during follow-up 
were also recorded.  
 
Safety 
Safety assessments included monitoring of adverse events and toxicity every 3-6 months during 
follow-up, through evaluation of vital signs, physical examinations, and regular monitoring of 
hematological and clinical biochemistry values as well as gallbladder ultrasonography study. We 
classified adverse events in accordance with the National Cancer Institute’s Common Terminology 
Criteria for Adverse Events version 4.0. 
 
Statistical analysis  
The statistical analysis was performed using the SPSS package version 20 (SPSS Inc., Chicago, IL, USA). 
Data were expressed as mean ± SD. Primary efficacy and safety analyses were conducted at end of 
study for all patients. PFS was analyzed graphically by using the Kaplan-Meier survival estimates. 
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Results 
 
 
Tumor response 
High dose SSA was administered for a mean follow-up of 29.9 ± 4.6 months (range 20-35). Ten (50%) 
patients were treated with octreotide LAR 60 mg every 28 days and 10 (50%) patients with 
lanreotide Autogel 120 mg every 21 days. During high dose SSA administration no other 
concomitant tumor-directed therapies were recorded. 
The mPFS was not reached. Antitumor efficacy of high dose SSA was evident in 16 (80%) patients. 
Partial ORR was recorded in 1 (5%) patient, stabilization in 15 (75%) and progression in 4 (20%). 
Treatment with octreotide LAR 60 mg/28d resulted in SD in 7 and PD in 3 patients. Treatment with 
lanreotide Autogel 120 mg/21d resulted in 1 ORR, 8 SD and 1 PD. The ORR was recorded in a patient 
with atypical bronchial carcinoid with liver metastases. There was no significant difference of mPFS 
according to type of SSA high dose schedule. 
 
Biochemical response 
Serum CgA levels were above the normal range at baseline in 16/20 (80%) patients. After high dose 
SSA, complete response was obtained in 3/16 (19%) and partial response in 9/16 (56%) patients. In 
3/16 (19%) CgA levels remained persistently elevated and in 1/16 (6%) patients CgA levels increased. 
CgA remained within the normal levels in the 4/20 (20%) patients with normal basal CgA levels (Fig 
1). 
Basal u5-HIAA was elevated in 4/5 (80%) patients with carcinoid syndrome and after high dose SSA 
partial response was obtained in 3 (75%) and stable levels in 1 (25%) patient. The patients with 
carcinoid syndrome and normal basal u5-HIAA showed no significative variations of this parameter 
during follow-up.  
Gastrin basal levels were elevated in all the 4 patients with Zollinger Ellison syndrome; after high 
dose SSA partial response was obtained in 2 (50%) patients and no response (persistently elevated) 
in 2 (50%) patients. In the patient with paraneoplastic acromegalic syndrome, IGF1 levels remained 
persistently elevated. 
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Octreotide LAR 60 mg/28d resulted in complete biochemical response in 2 (20%), partial response 
in 6 (60%), no response in 1 (10%) and progression in 1 (10%) patient.  
Lanreotide Autogel 120 mg/21d resulted in complete biochemical response in 1 (10%), partial 
response in 7 (70%) and no response in 2 (20%) patients. 
 
Clinical response 
Before starting high dose SSA, 12 (60%) patients presented clinical symptoms and 6 (30%) patients 
were asymptomatic. Among the 12 symptomatic patients, complete response was obtained in 1 
(8%), partial response in 6 (50%), no response in 4 (34%) and worsening of symptoms in 1 (8%). The 
6 (40%) asymptomatic patients did not develop clinical symptoms during follow-up.  
Octreotide LAR 60 mg/28d resulted in partial response in 4 and no response in 4. 
Lanreotide Autogel 120 mg/21d resulted in complete clinical response in 1, partial response in 2 and 
worsening in 1 patient. 
Among the most frequent symptoms, after high dose SSA, abdominal pain reported in 8 patients, 
completely disappeared in 1 patient, improved in 5 and persisted in 2; diarrhea, reported in 4 
patients, partially disappeared in 3 and persisted in 1; flushing, reported in 4 patients, improved in 
2 and remained stable in 2 (Table 6).  
 
Safety 
No treatment-related death was reported. High dose SSA were safe and well tolerated, no therapy 
withdrawal was recorded. In 4 (20%) patients asymptomatic cholelithiasis was diagnosed and 
treated with medical therapy. No other treatment-related adverse events were recorded. 
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Discussion 
 
 
Synthetic SSA, octreotide and lanreotide, represent the first-line therapy in patients with 
functioning NET due to their ability to control hormonal hypersecretion (31, 32). Although SSA have 
been developed as anti-hypersecretory agents, their antiproliferative efficacy in NET is now 
supported by clinical trials, PROMID and CLARINET, for octreotide and lanreotide, respectively (27, 
28). Furthermore, epidemiological data suggest the beneficial effects of SSA in terms of survival (3). 
Nevertheless, some patients escape from treatment, thus dose escalation of SSA has gradually 
become relatively common in clinical practice to overcome tachyphylaxis, and different hypotheses 
have been formulated to explain the reduction of efficacy of standard dose SSA in controlling both 
hormonal hypersecretion and tumor proliferation. Experimental data point out that tachyphylaxis 
could be related to the desensitization or internalization of somatostatin receptors as well as to the 
outgrowth of clones of tumor cells that lack somatostatin receptors. Dose escalation of SSA can be 
useful even in case of development of antibodies against SSA, injection site granulomas altering 
drug absorption, and heterogeneity in the expression of somatostatin receptor subtypes (37). 
Intratumoral heterogeneity may support the maintenance of SSA therapy beyond disease 
progression. Since not all tumor components become refractory simultaneously, SSA withdrawal 
may even worsen endocrine symptoms or lead to growth of stable lesions (50). An increase in the 
ORR has been initially demonstrated in acromegalic patient with high dose octreotide LAR (46, 47) 
as well as in NET with short acting SSA (38-41). Published data on the use of high dose long acting 
SSA are scattered and some retrospective reviews have analyzed the clinical employment of high 
dose SSA in NET. Nevertheless, prospective assessment of efficacy and tolerability of this common 
practice are scarce and there were no specifically designed clinical trials to explore high dose SSA. 
The present study prospectively evaluates the efficacy and safety of treatment with high dose of 
both commercially available SSA, octreotide and lanreotide, in patients with well or moderately 
differentiated, progressive NET of different origin. Two different schedules of high dose SSA were 
analyzed in patients with either symptomatic or radiological progression. 
The efficacy and safety of above dose octreotide LAR regimens were previously investigated in a 
review including 17 studies, varying in designs, subjects, octreotide-LAR regimens, and definition of 
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outcomes. It emerged that higher doses of octreotide LAR were used to control both symptoms and 
tumor progression, reporting efficacy and no evidence of increased toxicity (44).  
Our data highlight the effectiveness of high dose SSA therapy in progressive NET under standard 
SSA dose, either functioning or non-functioning. Median PFS was not reached and it can be related 
both to the relatively indolent behavior of the disease and to the duration of the study. In our series 
high dose SSA have demonstrated clinical efficacy in 80% of patients. Though the evaluation of 
therapeutic efficacy in NET is quite difficult due to their relatively indolent biological behavior, ORR 
has been obtained in 5%, while 75% of patients had stabilization of disease. Taking into account the 
advanced stage of disease in the majority of patients (65% stage IV) and the documented 
radiological progression during standard dose SSA in 18 out of 20 patients, we can already consider 
tumor stabilization as an effect of the antiproliferative activity of high dose SSA. 
Besides antiproliferative activity, high dose SSA therapy showed even biochemical and clinical 
effectiveness. In the 80% of cases with elevated basal CgA, complete response and partial response 
were obtained in 19% and 56%, respectively. Moreover, considering the specific markers evaluated 
for the different syndromes, partial response was obtained in 80% of carcinoid syndromes and in 
50% of Zollinger Ellison Syndromes. Although tumor marker levels may not be an accurate 
assessment of therapeutic efficacy, reduction in serum markers is frequently observed with high 
dose SSA (42, 51).  
In this study symptom score improved in 58% of symptomatic patients, although this aspect is 
difficult to evaluate due to patient self-assessment. Improvement of symptoms has already been 
reported with high dose octreotide in a review specifically addressing the relationship between 
octreotide dose escalation and symptoms control in NET. In this retrospective chart review including 
nonresectable metastatic NET patients who received a dose greater than 30 mg intramuscular 
octreotide LAR, dose escalation of octreotide LAR was associated with improvement of diarrhea, 
flushing, bronchoconstriction and abdominal pain in NET patients who were refractory to the 
standard dose SSA (51). 
In a recent systematic review, which included 18 studies and 1002 patients to systematically 
determine the efficacy and safety of escalated-dose SSA in clinical practice, disease control rates 
ranged from 30 to 100%, while response rates were modest (0-14%). Rates of biochemical 
improvement (27-100%) and symptoms improvement (23-100%) ranged widely depending on the 
population studied and the definition of response (52). There are now evidences that escalated dose 
SSA are well-tolerated in patients with GEP NET, with significant rates of disease control but low 
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rates of tumor response, and these recent data are consistent with the result of our prospective 
study. 
The analysis of safety profile of high dose SSA in our series was consistent with the pharmacology 
of the class, and no unexpected or unreported adverse events occurred. Treatment was never 
withdrawn, and adverse events included only asymptomatic cholelithiasis, which only required 
medical therapy. Specifically, cholelithiasis, as in most NET patients, seldom requires surgery and 
seems to be related more to treatment duration than to the dosage of SSA (53). A multicenter, 
prospective, open label, single arm phase II study with Lanreotide Autogel 180 mg/28 days for 12 
months in 35 patients with progressive NET under standard SSA dose, explored safety as primary 
endpoint and 2 treatment-related serious adverse events were reported, thus supporting 
substantial safety of treatment (54). 
In this study the efficacy of high dose SSA therapy has been demonstrated radiologically, clinically 
and biochemically. Nevertheless, the small sample size and the short follow-up of this study did not 
allow to find any correlation among sex, site of primary NET, functional status, and response to high 
dose SSA in terms of PFS and TTP. Nevertheless, our data suggest that high dose SSA are effective 
in NET of different origin, progressive under standard dose SSA, functioning or nonfunctioning, and 
show good safety profile. Data from systematic prospective trials specifically designed to evaluate 
the safety and efficacy of high dose schedules in NET are still lacking, nevertheless recent trials such 
as NETTER-1 already consider high dose SSA to be the standard control arm after progression (55). 
Furthermore, international guidelines have recently updated their algorithms including high dose 
SSA among the therapeutic options in patients with progressive NET (12, 56). The efficacy of high 
dose SSA could allow to delay the need of other systemic or invasive locoregional therapies, which 
are associated with higher morbidity and toxicity than SSA. Further prospective, randomized studies, 
with large number of patients and longer duration of follow-up are required to understand if our 
preliminary data would translate into a real survival advantage as well as to identify the most 
effective option among high dose SSA schedules, possible predictors for response and the amount 
of delay of other more toxic treatments.  
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Tables and figures 
 
 
Table 1. WHO classification of gastroenteropancreatic neuroendocrine neoplasms (NEN) 
 
 
 
 
 
 
 
 
1HPF, High Power Field 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ki 67 (%) Mitotic index 
(x HPF1) 
Well Differentiated NEN   
Neuroendocrine tumor (NET) G1 ≤ 2 < 2/10 
Neuroendocrine tumor (NET) G2 3-20 2-20/10 
Poorly Differentiated NEN   
Neuroendocrine carcinoma (NEC) G3 > 20 > 20/10 
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Table 2. WHO Classification of pulmonary neuroendocrine neoplasms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Typical 
Carcinoid 
 
Atypical 
Carcinoid 
 
Large Cell 
Neuroendocrine 
Carcinoma 
Small Cell 
Carcinoma 
 
Mitoses per 2 
mm2 
0-1 2-10 > 20 (median 70) > 10 (median 80) 
Necrosis No Focal, if any Yes Yes 
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Table 3. Functioning neuroendocrine neoplasms 
 Signs/ 
symptoms 
 
Secreted 
peptide(s) 
Primary site 
 
Biochemical 
marker(s) 
 
Carcinoid 
Syndrome 
 
Flushing, diarrhea, 
abdominal pain, 
bronchoconstriction, 
tricuspid and 
pulmonic 
valve regurgitation 
 
Serotonin 
Tachykinins, 
Neurokinins 
 
Jejunum / ileum 
(pancreas, lung, 
rectum) 
 
u5-HIAA1, CgA2, 
NTproBNP3 
 
Insulinoma 
 
Hypoglycemia and 
rapid 
improvement after 
glucose (Whipples’ 
triad) 
 
Insulin 
 
Pancreas 
 
72-h fasting test 
(Plasma glucose, 
Insulin, C-
peptide, ß-
hydroxybutyrate) 
 
Zollinger-Ellison-
Syndrome 
(Gastrinoma) 
 
Severe peptic ulcer 
disease, 
gastroesophageal 
reflux, diarrhea 
 
Gastrin 
 
Duodenum 
(70%) pancreas 
(25%); 
other sites (5%) 
 
Fasting serum 
gastrin, gastric 
pH secretin-
stimulation test 
 
VIPoma (Werner 
Morrison 
Syndrome; 
WDHA4) 
 
Watery diarrhea, 
hypokalemia, 
achlorhydria/ 
acidosis 
 
Vasoactive 
intestinal 
peptide (VIP) 
 
Pancreas > 90% 
 
Plasma VIP 
 
Glucagonoma 
 
Diabetes, necrolytic 
migratory erythema, 
weight loss, nausea 
 
Glucagon 
 
Pancreas 
 
Serum glucagon 
 
 
1u5-HIAA, urinary 5-hydroxyindoleacetic acid; 2CgA, Chromogranin A; 3NTproBNP, N-terminal pro b-type natriuretic 
peptide; 4WDHA, watery diarrhea, hypokaliemia, achlorhydria/acidosis 
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Table 4. Biomarkers in NET 
Biomarker 
 
Site of primary tumor 
 
Sensitivity 
 
Specificity 
 
Chromogranin A 
 
All sites  
 
43-100% 
 
10-96% 
 
u5-HIAA1 
 
Midgut 
 
35% 
 
Up to 100% 
 
Gastrin 
 
Stomach, duodenum, 
pancreas 
 
Up to 100% 
 
<20% 
 
Insulin 
 
Pancreas 
 
Up to 100% 
 
<20% 
 
Pancreatic polypeptide 
 
Pancreas, midgut 
 
31-63% 
 
Up to 67% 
 
 
1u5-HIAA, urinary 5-hydroxyindoleacetic acid 
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Table 5. Patients’ characteristics 
Parameter 
 
Number of patients (%) 
Patients 20 
Male/female 14 (70) /6 (30) 
  
Sporadic/MEN1-associated NET 12 (60) / 8 (40) 
  
Site of primary tumor  
Pancreas 10 (50) 
Ileum 5 (25) 
Duodenum 1 (5) 
Rectum 1 (5) 
Bronchial 2 (10) 
Unknown primary 1 (5) 
  
Grading  
G1 12 (60) 
G2 8 (40) 
  
Ki67 (%)  
≤ 2 12 (60) 
3-20 8 (40) 
  
Staging  
Primary tumor without metastases 5 (25) 
Locoregional lymph nodes 2 (10) 
Liver metastases 13 (65) 
  
Prior surgery 8 (40) 
  
Octreoscan positivity 9 (45) 
  
68GaPET positivity 11 (55) 
  
Non-functioning NET 10 (50) 
  
Functioning NET 10 (50) 
Zollinger Ellison syndrome 4 (40) 
Carcinoid syndrome 5 (50) 
Acromegaly 1 (10) 
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Table 6. Clinical response during high dose SSA therapy 
Symptom Patients Complete 
response 
Partial 
response 
No 
response 
Progression 
Abdominal pain 8 1 5 2 0 
Diarrhea 4 0 3 1 0 
Flushing 4 0 2 2 0 
Dyspnea 2 0 1 1 0 
Cough 2 0 1 1 0 
Pyrosis 4 1 3 0 0 
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Figure 1. Biochemical response in 16/20 patients with Cromogranin A (CgA) levels above the 
normal range at baseline:  complete response (CR) was obtained in 3/16 (19%) and partial 
response (PR) in 9/16 (56%) patients. In 3/16 (19%) CgA levels remained persistently elevated (NR, 
no response) and in 1/16 (6%) patients CgA levels increased (PD, progressive disease) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
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20
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40
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